today lost a seven-year long legal battle for getting its blood cancer
drug Glivec patented in India and
to restrain Indian companies from
manufacturing generic drugs, with
the Supreme Court rejecting the
multinational company's plea. A
bench of justices Aftab Alam and
Ranjana Prakash Desai dismissed
the claim of the Swiss firm for
getting exclusive rights for
manufacturing the cancer drug on
the ground that a new substance
has been used in the medicine. The
judgement, which was keenly
watched by pharma companies
across the world, will clear hurdles
coming in the way for the
manufacture of generic drugs in
India for cancer patients.
Amazon Unbelievable Offers at 50% OFF on Health Products, Books, DVD & more .
No comments:
Post a Comment